AKT1 and cancer: One derivative of NSC23766, EHop-016, inhibits Rac activation through disrupting its direct binding to Vav2 (a Rho-specific GEF) [113], giving it a 100-fold lower IC50 against this GTPase than NSC23766, which encourages its use instead its derivative in cancer therapy [113,114,115,116].